- Home
- NVS
NVS
Novartis AG
as 08-08-2025 10:39am EST
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 242.8B | IPO Year: | 1991 |
| Target Price: | $123.67 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 6.85 | EPS Growth: | -12.59 |
| 52 Week Low/High: | $96.06 - $124.83 | Next Earning Date: | 07-17-2025 |
| Revenue: | $55,186,000,000 | Revenue Growth: | 12.95% |
| Revenue Growth (this year): | 8.96% | Revenue Growth (next year): | 2.34% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda
GlobeNewswire
a day ago
Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical
Investor's Business Daily
2 days ago
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
MT Newswires
2 days ago
Sector Update: Health Care Stocks Slide Late Afternoon
MT Newswires
2 days ago
Sector Update: Health Care Stocks Fall Wednesday Afternoon
MT Newswires
2 days ago
Sector Update: Health Care
Pharmaceutical Technology
2 days ago
Teva’s Ajovy becomes first migraine prevention drug approved for children
GlobeNewswire
2 days ago
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.